Quality assurance systems of pharmaceutical distributors in low-income and middle-income countries: weaknesses and ways forward.
Ariadna Nebot GiraltAnthony BourasseauGareth WhiteCorinne PougetPatricia TaberneroKerlijn Van AsscheRaffaella RavinettoPublished in: BMJ global health (2021)
The quality systems of pharmaceutical distributors in LMICs remain weak. For preventing harm caused by poor-quality medicines, a comprehensive and stringent regulatory oversight should be urgently implemented; the WHO MQAS-standards and GDP-standards should be incorporated in national regulations; and reliable information on the quality systems of distributors (and manufacturers from which they buy) should be publicly available.